New prostate cancer drug may cause fewer side effects than current option
NCT ID NCT05526248
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two drugs, darolutamide and enzalutamide, in 28 men with prostate cancer that had returned after initial treatment. The goal was to see how each drug affects testosterone levels and side effects like breast tenderness. Darolutamide may cause fewer of these side effects because it doesn't enter the brain as easily. The study is small and early, so more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Darolutamide (Nubeqa) and Enzalutamide
- What this could lead to
- If successful, this study could show that darolutamide causes fewer side effects like breast tenderness while still controlling prostate cancer, offering a better-tolerated treatment option.
- What could go wrong
- This is a small, early-phase study with only 28 participants, so results may not apply to all patients. It compares two drugs but does not test against a placebo or standard therapy, limiting what can be concluded.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center - Oncology
Boston, Massachusetts, 02215, United States
-
Central Ohio Urology Group - Gahanna
Gahanna, Ohio, 43230, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114-2696, United States
-
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York, 10065, United States
-
Unio Specialty Care - Urology - Sherman Oaks
Sherman Oaks, California, 91411, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.